Lv1
20 积分 2023-03-12 加入
Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial
9小时前
已完结
Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development
15天前
已完结
Peripheral blood neutrophils contribute to Claudin18.2-specific CAR-T cell treatment resistance in advanced gastric cancer
29天前
已完结
Colistin Monotherapy versus Combination Therapy for Carbapenem-Resistant Organisms
2年前
已关闭
皖公网安备34019202002308
